Mylicon Gocce oral solution

Mylicon is a well-established pharmaceutical brand specializing in infant gas relief, specifically using simethicone to treat symptoms of gastrointestinal meteorism and aerophagia. Originally developed and popularized under the Johnson & Johnson umbrella, the brand has a long history of trust among pediatricians and parents globally.

In the Italian market, Mylicon Gocce (oral drops) is manufactured and distributed through local facilities ensuring compliance with European Medical Device Regulations (MDR). The brand's ownership has recently undergone a major corporate shift. Formerly part of Johnson & Johnson’s Consumer Health division, it was moved to Kenvue, a standalone consumer health company spun off in 2023. As of late 2025 and moving into 2026, the brand is part of a larger global health and wellness portfolio following Kimberly-Clark's acquisition of Kenvue, marking a significant transition in its corporate lineage while maintaining its legacy of specialized infant care.